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Sequence variants at the TERT-CLPTM1L
locus in chromosome 5p have been re-
cently associated with disposition for vari-
ous cancers. Here we show that this
locus including the gene encoding the
telomerase reverse-transcriptase TERT at
5p13.33 is rarely but recurrently targeted
by somatic chromosomal translocations
to IGH and non-IG loci in B-cell neo-
plasms, including acute lymphoblastic
leukemia, chronic lymphocytic leukemia,
mantle cell lymphoma and splenic mar-
ginal zone lymphoma. In addition, cases
with genomic amplification of TERT locus
were identified. Tumors bearing chromo-
somal aberrations involving TERT showed
higher TERT transcriptional expression
and increased telomerase activity. These
data suggest that deregulation of TERT
gene by chromosomal abnormalities lead-
ing to increased telomerase activity might
contribute to B-cell lymphomagenesis.
(Blood. 2010;116(8):1317-1320)
Introduction
Chromosomal translocations to the immunoglobulin heavy chain
(IGH) or light chain (IGL or IGK) loci, and less frequently to
non-IG loci represent well known mechanisms of oncogene
activation in B-cell neoplasms.1,2 Many of the genes deregulated by
chromosomal translocations in these neoplasms are involved in
important cellular processes like cell-cycle control (CCND1,
CCND3, BCL6, and CDK6), apoptosis (BCL2), proliferation (MYC),
or signal transduction (BCL3 and MALT1).1
Telomere maintenance across cell divisions is essential for
tumor cell growth and immortalization.3 Here, we provide evidence
that the telomerase reverse-transcriptase (TERT) gene at 5p13.33,
which encodes for the rate-limiting catalytic protein subunit of the
telomerase,4-6 is deregulated by chromosomal translocations to IG
and non-IG loci in precursor and mature B-cell malignancies.
Methods
Patient samples
The features of B-cell malignancies showing aberrations in the TERT region
(5p1) are listed in supplemental Table 1 (available on the Blood Web site; see the
Supplemental Materials link at the top of the online article). The study was
performed as part of the “Molecular Mechanisms in Malignant Lymphoma”
Network Project for which approval from the Institutional Review Board of the
Medical Faculity of the Christian-Albrechts-University Kiel has been obtained.
FISH
Fluorescence in situ hybridization (FISH) was performed on fixed cells
from bone marrow, peripheral blood, or lymph node cell suspensions as
described previously.7 Generation of FISH probes as well as FISH
procedures are described in supplemental Methods. A list of FISH probes
used is shown in supplemental Table 2.
Array CGH to custom-designed arrays
The microarrays were designed using the eArray software from Agilent
(https://earray.chem.agilent.com/earray/) and the 4 44k format. The
experimental procedures were performed according to the manufacturer’s
instructions. Arrays were scanned with the GenePix4000B Scanner (Axon
Instruments) and log ratios obtained with the comparative genomic
hybridization (CGH) Analytics Version 3.5.14 software (Agilent). All
microarray data are available to be viewed at ArrayExpress under accession
number E-MEXP-2675 (http://www.ebi.ac.uk/miamexpress/).
Quantitative reverse transcription PCR
RNA was extracted from tumor cell–containing samples and control tissue,
using the RNeasy Mini Kit (QIAGEN) and transcribed into cDNA with the
QuantiTect Rev. Transcription Kit (QIAGEN). TERT transcripts were
amplified and detected as described elsewhere.8
TRAP assay
The PCR-based telomeric repeat amplification protocol (TRAP) assay was
performed as described previously.9,10 Protein from tumor cell containing
samples and control tissue was isolated according to Kim et al.11
Additional information about materials and methods is available in
supplemental Methods.
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Results and discussion
By FISH screening of B-cell neoplasms for translocations affecting
the IGH locus we observed a cytogenetically cryptic translocation
t(5;14)(p15;q32) involving the IGH locus in 3 cases of chronic
lymphocytic leukemia (CLL) and one case of precursor B-cell
acute lymphoblastic leukemia (ALL; Figure 1A-C). The break-
points in 5p15.33 in all 4 cases mapped to a region containing the
TERT (telomerase reverse transcriptase; chr5: 1.306 Mb to 1.348
Mb) and CLPTM1L (cleft lip and palate transmembrane 1–like;
chr5: 1.371 Mb to 1.398 Mb) genes (Figure 1D-F, supplemental
Table 1).
The IGH locus harbors strong transcriptional enhancers, which
can activate oncogenes by translocation on both der(14) and der(5)
chromosomes12 (supplemental Figure 1). FISH mapping showed
the TERT gene juxtaposed to the IGH locus indicating TERT
translocation to der(14) in all 4 cases. The signal patterns indicated
CLPTM1L to be disrupted by the translocation in case 1 (Figure
1D). In case 2, the breakpoint was associated with an interstitial
deletion resulting in loss of CLPTM1L (Figure 1E). This deletion
was confirmed by high-resolution array CGH, which also allowed
fine-mapping the translocation breakpoint to a repeat-rich region
centromeric of TERT (1.354 Mb to 1.366 Mb; supplemental Figure
2A). The 5p15.33 breakpoints of cases 3 and 4 were shown to be
between TERT and CLPTM1L (Figure 1F).
To investigate the frequency of rearrangements in the TERT-
CLPTM1L region we screened additional cases by FISH (supple-
mental Figure 3, supplemental Table 1). Among 34 lymphoid
neoplasms, in which conventional cytogenetics revealed an aberra-
tion in 5p1, 5 cases showed breaks and one case showed amplifica-
tion at the TERT-CLPTM1L region. Four of these 6 cases were
diagnosed as mantle cell lymphomas (MCLs). Thus, we extended
the screen to 123 primary MCLs without known 5p1 abnormality
and identified 2 additional cases, one with break (Figure 1G) and
one with amplification at the TERT-CLPTM1L region (supplemen-
tal Table 1).
None of the additional 6 cases with translocations detected by
FISH showed juxtaposition to any of the 3 IG loci. Cytogenetically,
in 4 of the 6 variant translocations (ie, non-IG), 7p11, 9q3133,
10q25 and 19p13 were identified as partners of 5p15. In a splenic
marginal zone lymphoma (SMZL, case 5) with t(5;7)(p15.33;p11),
FISH and tiling array CGH again confirmed a breakpoint centro-
meric to TERT with loss of CLPTM1L similar to that in the
t(5;14)-positive CLL mentioned above (Figure 1E, supplemental
Figure 2B). Except for the SMZL case, the remaining 5 additional
cases showed the same breakpoint in 5p15.33 as in cases 3 and
4 (Figure 1F).
The inactivation of CLPTM1L by deletion and disruption in
3/10 cases with break at the TERT-CLPTM1L region and also the
fact that in precursor B-cell ALL with IGH translocation oncogene
activation has always been assigned to the der14 chromosome13
(supplemental Figure 1) strongly supports TERT to be the gene
targeted by these aberrations.
To investigate the effect of the identified chromosomal aberra-
tions on TERT expression, we performed qRT-PCR in cases with
t(5;14)/TERT-IGH juxtaposition (n 3; Figure 2A for CLL,
supplemental Figure 5 for ALL) and 5p15.33 variant translocations
(n  5; Figure 2A, supplemental Figure 4 for MCL) where suitable
material was available. Significantly increased TERT mRNA
expression was observed in all 3 CLLs and the SMZL with a break
in the TERT-CLPTM1L region compared with eleven CLLs
without aberration at the TERT-CLPTM1L region as detected by
FISH (Figure 2A). Similarly, the 3 MCLs with break in 5p15.33
showed higher TERT mRNA expression compared with 5 MCLs
without break in the TERT-CLPTM1L region and controls (supple-
mental Figure 4). The ALL with t(5;14) displayed high TERT
expression but this was also detected in 6 ALL cases without such a
change (supplemental Figure 5). These findings show that indepen-
dent of the presence of centromeric (CLPTM1L) deletions or the
translocation partner, rearrangements affecting the TERT-CLPTM1L
region are associated with high TERT expression.
Figure 1. Characterization of chromosomal aberrations affecting the TERT-
CLPTM1L locus. IGH FISH (A) and R-banding analysis (B) of the same metaphase
of case 1 showing the cytogenetic cryptic t(5;14). (C) Interphase FISH showing a
fusion of IGH and the TERT-CLPTM1L locus in case 1. (D-F) Schematic maps of the
breakpoint regions in cases with t(5;14)(p15;q32) based on FISH mapping. Black
bars indicate the hybridized BAC and Fosmid clones; gray bars represent the genes
in the region. The breakpoint regions were determined by the respective FISH
hybridization patterns. (G) FISH using the TERT-CLPTM1L 3-color break-apart
assay on MCL case 10 showing break in the clone RP11-117B23 (blue signal). The
R-banding image with Chromomycin A3 (C2659, Sigma-Aldrich) and Methyl green
(M8884, Sigma-Aldrich) was obtained using a 63/1.40 numeric aperture oil
objective in a Zeiss Axioskop Imager M1 fluorescence microscope (Zeiss) with
R-banding filter sets (Zeiss) and documented using the IKAROS imaging system
version 5.2.11 (MetaSystems). FISH images were acquired using a 63/1.40
numeric aperture oil objective in a Zeiss Axioskop 2 fluorescence microscope (Zeiss)
equipped with the appropriate filter sets (AHF) and documented using a CV-M300
camera (JAI Corporation) and the ISIS imaging system Version 5.2.11 (MetaSys-
tems). dist indicates distal; and prox, proximal.
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We next assessed whether the up-regulation of TERT mRNA
was also associated with increased telomerase activity. Using the
TRAP assay, cases of CLL (cases 1 and 6) and MCL (cases 8 and
9) with chromosomal breakpoints at the TERT-CLPTM1L locus
showed markedly higher telomerase activity compared with
appropriate disease and tissue controls (Figure 2B, supplemental
Table 3).
Taken together, we show that the TERT-CLPTM1L region in
5p15 is recurrently targeted by chromosomal translocations in
B-cell neoplasms. Based on the finding that CLPTM1L is recur-
rently lost or disrupted by the mentioned aberrations, it does not
seem to contribute to the process of lymphomagenesis. Interest-
ingly, germ line sequence variants in the TERT-CLPTM1L region
were recently shown to be associated with predisposition for
several cancer types.14-17 All 6 additional translocations and both
amplifications identified herein were of somatic origin as cells
without the aberration were always present. The pattern of IGH
translocations as well as the increased TERT expression and
telomerase activation in cases with 5p15 translocations strongly
suggest TERT to be the candidate gene involved in lymphomagen-
esis. Telomerase activity, which is clearly detectable in up to 90%
of human tumors, including hematologic neoplasias, but not in
most normal somatic cells, is in part explained by changes in
chromatin structure or amplification of the TERT locus.11,18-20
Moreover activation of TERT transcription through viral integra-
tion into the TERT promoter has been shown to be associated with
B-cell lymphoma and other tumors.21,22 Remarkably, on the
cytogenetic level the t(5;14)/IGH-TERT was the sole abnormality
in one case of CLL, suggesting TERT deregulation to be an early
event in lymphomagenesis. This is in accordance with the recent
observation that mice with constitutive expression of TERT in
thymocytes and peripheral T cells are prone to develop T-cell
lymphomas, which are more invasive than those of wild-type mice
and may be explained by the recent finding that TERT acts,
independent of telomerase activity, as a cofactor in the Wnt
pathway.23,24 Remarkably, TERT translocations might not be re-
stricted to lymphatic neoplasms as a recent study by Zhao et al also
identified a translocation breakpoint within CLPTM1L in the breast
cancer cell line HCC1954 similar to one case of CLL (case 1) with
translocation t(5;14)(p15;q32) described herein.25
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